WAVE Stock Overview
Waverley Pharma Inc., a biopharmaceutical company, researches, develops, and commercializes cancer therapeutics in the United Kingdom.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Waverley Pharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.035 |
| 52 Week High | CA$0.04 |
| 52 Week Low | CA$0.015 |
| Beta | 1.43 |
| 1 Month Change | 0% |
| 3 Month Change | 40.00% |
| 1 Year Change | 40.00% |
| 3 Year Change | -75.00% |
| 5 Year Change | -77.42% |
| Change since IPO | -93.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| WAVE | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | 0% | -6.4% | -2.1% |
| 1Y | 40.0% | -35.6% | 3.6% |
Return vs Industry: WAVE exceeded the Canadian Biotechs industry which returned -33.7% over the past year.
Return vs Market: WAVE exceeded the Canadian Market which returned 3.2% over the past year.
Price Volatility
| WAVE volatility | |
|---|---|
| WAVE Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 13.7% |
| Market Average Movement | 9.2% |
| 10% most volatile stocks in CA Market | 18.4% |
| 10% least volatile stocks in CA Market | 3.1% |
Stable Share Price: WAVE's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine WAVE's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Larry Thiessen | www.waverleypharma.com |
Waverley Pharma Inc., a biopharmaceutical company, researches, develops, and commercializes cancer therapeutics in the United Kingdom. It focuses on the generic oncology injectable products. The company sells generic oncology products comprising capecitabine, temozolomide, and erlotinib.
Waverley Pharma Inc. Fundamentals Summary
| WAVE fundamental statistics | |
|---|---|
| Market cap | CA$1.35m |
| Earnings (TTM) | -CA$1.10m |
| Revenue (TTM) | CA$542.61k |
3.5x
P/S Ratio-1.7x
P/E RatioIs WAVE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| WAVE income statement (TTM) | |
|---|---|
| Revenue | CA$542.61k |
| Cost of Revenue | CA$381.17k |
| Gross Profit | CA$161.44k |
| Other Expenses | CA$1.26m |
| Earnings | -CA$1.10m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.02 |
| Gross Margin | 29.75% |
| Net Profit Margin | -202.32% |
| Debt/Equity Ratio | 591.9% |
How did WAVE perform over the long term?
See historical performance and comparison